Detectability of pancreatic lesions by low-dose unenhanced computed tomography using iterative reconstruction.

Abstract

OBJECTIVES\nTo investigate the detectability of pancreatic cystic lesions and main pancreatic duct dilation by low-dose unenhanced computed tomography (CT).\n\n\nMATERIAL AND METHODS\nThis study included 2684 patients who underwent low-dose unenhanced CT using iterative reconstruction and magnetic resonance imaging (MRI) as a part of a health-screening program between February 1, 2019 and December 31, 2019. Patients diagnosed with pancreatic cystic lesions and/or dilatations of the main pancreatic duct on MRI were identified. Detection rates by low dose CT in terms of lesion size were tested for significance by Fisher s exact test.\n\n\nRESULTS\nOf the 2684 patients, 558 (20.8 %) had pancreatic cystic lesions and 22 (0.8 %) had main pancreatic duct dilatation on MRI. The low-dose CT detection rates among the pancreatic cystic lesions were as follows: 1-9-mm cysts, three (0.65 %) of 461; 10-19-mm cysts, 17 (21.25 %) of 80, and ≥20-mm cysts, eight (47.06 %) of 17. The detection rates were significantly higher in the 10-19-mm and the ≥20-mm cyst group than in the 1-9-mm cyst group (p\u202f<\u202f 0.001). The detection rates among the main pancreatic duct dilatations were as follows: 3-5-mm dilatations, two (11.76 %) of 17 and ≥6-mm dilatations, four (80 %) of five, which were significantly higher rates than that for the 3-5-mm dilatations (p\u202f=\u202f 0.009).\n\n\nCONCLUSION\nSmall pancreatic cysts and slight main pancreatic duct dilatation were practically undetectable by low-dose unenhanced CT. The application of a low-dose CT protocol as a screening tool in the detection of pancreatic abnormalities is not recommended.